Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta‐analysis. (8th September 2017)

• Record Type: Journal Article
• Authors: Babary, Hamayon; Liu, Xibei; Ayatollahi, Yosef; Chen, Xin P.; Doo, Loomee; Uppaluru, Lakshmi K.; Kwak, Myoung K.; Kulaga, Catherine; Modjinou, Dodji; Olech, Ewa; Yoo, Ji W.
• Is Part Of: International journal of rheumatic diseases. Volume 21:Number 1(2018)
• Page Start: 84
• Page End: 92
• Publication Date: 2017-09-08
• Subjects: chloroquine -- lipid metabolism disorder -- systemic lupus erythematosus; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.13159
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Aims: Hydroxychloroquine (HCQ) has shown to have significant immunomodulatory effects in the treatment of systemic lupus erythematosus (SLE). Current studies show favorable effects of HCQ on traditional cardiac risk factors in patients with SLE. This review examined the effects of HCQ on serum low‐density lipoprotein (LDL) level in patients with SLE. Methods: A systematic search of seven major literature search databases from their inception until 3 April, 2017 identified nine studies. Random‐effects pooled mean difference with corresponding 95% confidence intervals (CI) were estimated. Heterogeneity was measured by I 2 . Publication bias was assessed by visual inspection of funnel plots. Sensitivity analysis examined whether HCQ effect on serum total cholesterol level was similar to the main analysis. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the overall quality of evidence. Results: Pooled study participants were 559 patients from eight observation studies (two before‐after studies; six case‐control studies) examining the effects of HCQ on serum LDL. Pooled study participants' characteristics were as follows: mean age 45.719, female 95.262%, and prednisone use 58.366%. HCQ reduced mean LDL levels by 24.397 mg/dL (95% CI 8.921–39.872; P = 0.002). The number of studies identifying statin use was too few to perform meta‐regression analysis of statin use. Heterogeneity was extensive ( I 2 = 94.739%). Symmetrical funnel plot visualized no evidence of publication bias. Conclusion: HCQ was associated with serum LDL level reduction by mean 24.397 mg/dL in patients with SLE. Future prospective studies are need to fully characterize the treatment effect.